

# REVIEWS OF THERAPEUTICS

## Management of Self-injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview

Ashley Sabus,<sup>1</sup> James Feinstein,<sup>2,3,4</sup> Patrick Romani,<sup>5,6</sup> Edward Goldson,<sup>3,4</sup> and Allison Blackmer<sup>1,7,8\*</sup> 

<sup>1</sup>Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado; <sup>2</sup>Adult and Child Consortium for Health Outcomes Research & Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora, Colorado; <sup>3</sup>Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado; <sup>4</sup>Children's Hospital Colorado, Aurora, Colorado; <sup>5</sup>Child and Adolescent Psychiatry, Children's Hospital Colorado, Aurora, Colorado; <sup>6</sup>Department of Psychiatry, University of Colorado School of Medicine, Aurora, Colorado; <sup>7</sup>Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado; <sup>8</sup>Special Care Clinic, Children's Hospital Colorado, Aurora, Colorado

Neurodevelopmental disorders (NDDs), a group of disorders affecting ~1–2% of the general population, are caused by changes in brain development that result in behavioral and cognitive alterations, sensory and motor changes, and speech and language deficits. Neurodevelopmental disorders encompass a heterogeneous group of disorders including, but not limited to, Smith-Magenis syndrome, Lesch-Nyhan disease, cri du chat syndrome, Prader-Willi syndrome, pervasive developmental disorders, fragile X syndrome, Rett syndrome, Cornelia de Lange syndrome, and Down syndrome. Self-injurious behaviors (SIBs) are common in children with NDDs; depending on the specific NDD, the incidence of SIBs is nearly 100%. The management of SIBs in this population is complex, and little high-quality data exist to guide a consistent approach to therapy. However, managing SIBs is of the utmost importance for the child as well as the family and caregivers. Behavior therapies must be implemented as first-line therapy. If behavioral interventions alone fail, pharmacotherapy becomes an essential part of management plans. The limited available evidence for the use of common pharmacologic agents, such as second-generation antipsychotics, and less common agents, such as clonidine, n-acetylcysteine, riluzole, naltrexone, and topical anesthetics, is reviewed. Additional data from well-designed studies in children with NDDs are needed to gain a better understanding of this common and troublesome problem including efficacy and safety implications associated with pharmacotherapy. Until then, clinicians must rely on the limited available data, clinical expertise, and ongoing systematic monitoring when managing SIBs in children with NDDs.

**KEY WORDS** children, neurodevelopmental disorders, pediatrics, pharmacotherapy, self-injurious behaviors.

(Pharmacotherapy 2019;39(6):645–664) doi: 10.1002/phar.2238

---

Conflicts of Interest: The authors have declared no conflicts of interest for this article.

\*Address for correspondence: Allison Blackmer, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, and Clinical Pharmacist Specialist- Special Care Clinic (Children's Hospital Colorado), Mail Stop C238, 12850 E. Montview Blvd., V20-1208, Aurora, CO 80045; e-mail: allison.blackmer@ucdenver.edu  
© 2019 Pharmacotherapy Publications, Inc.

Self-injurious behaviors (SIBs) are nonnormative behaviors performed with the intent of physical self-harm but without the intent to die.<sup>1</sup> Self-injurious behaviors include self-directed repetitive actions such as biting, hitting, head and limb banging, face slapping, hair pulling, and eye poking that can result in severe injury and represent a troubling problem for patients and caregivers alike.<sup>2, 3</sup> These SIBs can occur in two groups of individuals: those with psychopathologic conditions such as depression, borderline personality disorder, and eating disorders that typically involve nonsuicidal self-injury such as cutting; and those with neurodevelopmental disorders (NDDs) that involve the behaviors just described.<sup>1</sup> This review focuses on SIBs specific to children with NDDs.

Neurodevelopmental disorders, defined as disorders caused by changes in early brain development resulting in behavioral and cognitive alterations, changes in sensory and motor systems, and speech and language deficits, affect roughly 1–2% of the population.<sup>4–8</sup> The prevalence and expression of SIBs in children with NDDs is variable. A comprehensive discussion of all NDDs is outside the scope of this review; however, a brief description of select childhood-related NDDs and associated SIBs is included for completeness (Table 1).<sup>1, 2, 9–28</sup>

Several risk factors have been identified for the development of SIBs in children with NDDs including severity of disease, language deficits, deficiencies in daily living skills, concomitant overactivity and impulsivity, sensory and motor impairments, repetitive behaviors, sleep disturbance, and, most significantly, the degree of intellectual disability.<sup>1–3, 29</sup> Other contributing factors may include comorbid medical conditions such as urinary incontinence, pain, constipation, headache, menstruation, and depression.<sup>15, 30</sup> SIBs may be observed as early as 6 months of age in children with NDDs, gaining full expression by the age of 5 years, and may persist throughout the life span.<sup>4–8</sup> The impact of SIBs on the patient as well as caregivers is profound, with SIBs commonly reported as one of the most negative influences on quality of life.<sup>7, 8</sup> Clinical, social, financial, and emotional burdens are high.<sup>31</sup> Patients, caregivers, and clinicians alike are regularly desperate for relief and solutions.

The underlying etiology and pathophysiology of SIBs in children with NDDs are poorly understood and may vary between NDDs. Several

theories have been purported, although a direct link to SIBs has not been conclusively elucidated. One theory involves the concept of environmental impoverishment.<sup>2</sup> Children with NDDs often have impaired communication that leads to socialization deficits and a lack of stimulation from the environment. The resulting social and environmental isolation promotes the expression of SIBs, perhaps as a means of communication, attention seeking, and social reinforcement.<sup>1–3</sup> SIBs may occur as a means of escaping nonpreferred activities (i.e., negative reinforcement), to gain access to attention and/or preferred activities (i.e., positive reinforcement), or for its own consequences (i.e., automatic reinforcement); attention and escape are the most commonly identified functions of SIBs.<sup>32</sup> Other theories include physical discomfort and illness, state of overarousal exacerbated by environmental stimuli, sensory reinforcement, disruption in the pain-endogenous opioid system, and alterations in neurotransmitters such as dopamine, serotonin,  $\gamma$ -aminobutyric acid (GABA), and glutamate.<sup>33–35</sup>

The management of SIBs is complex, and the optimal approach to therapies (nonpharmacologic and pharmacologic) is not well defined. Little high-quality evidence exists to guide a consistent therapeutic approach. Most of the knowledge pertaining to the management of SIBs comes from data in individuals with autism spectrum disorder (ASD), rather than other specific NDDs. Additionally, available assessment measures and objective scales to evaluate SIBs commonly evaluate problem behaviors (e.g., aggression, irritability, tantrums, and SIBs) in aggregate rather than SIBs specifically, although each type of behavior has distinct features that may require different treatment approaches.<sup>8, 16</sup> Despite these clinical challenges, SIB management is necessary due to the severity and impact of SIBs on the quality of life, and pharmacotherapy often becomes a necessary part of the treatment plan.

This article provides an overview of pharmacologic approaches available in the management of SIBs associated with NDDs. Relevant information was identified through PubMed via a structured literature search using relevant search terms (Table S1). Given the scarcity of research on the pharmacologic management of SIBs and the heterogeneity of study designs, the intent was not to perform a systematic review or meta-analysis. Rather, a narrative summary of

Table 1. Review of Select Specific Neurodevelopmental Disorders<sup>a</sup> Associated with Self-Injurious Behaviors<sup>b</sup>

NDD	Etiology	Clinical Characteristics	Prevalence	Incidence of SIBs	Specific SIBs
Smith-Magenis syndrome <sup>1, 9</sup>	Usually caused by deletions in the 17p11.2 region; a mutation in the <i>RAI1</i> gene is associated with SIBs	Brachycephaly, midface hypoplasia, hoarse voice, speech delay, psychomotor and growth delay, cutaneous feature, behavior problems, hypotonia	1:15,000–1:25,000 live births	Nearly 100% of patients will have SIB	<ul style="list-style-type: none"> <li>• Biting</li> <li>• Hitting</li> <li>• Picking at fingernails and toenails</li> <li>• Insertion of foreign objects into orifices</li> </ul>
Lesch-Nyhan syndrome <sup>10</sup>	Mutation in hypoxanthine-guanine phosphoribosyl-transferase 1 (HPRT <sup>c</sup> )	Hyperuricemia, choreoathetoid movement, intellectual disability, aggression toward others	1:380,000 live births	When < 1.5% HPRT enzyme is present, nearly 100% of patients will have SIB	<ul style="list-style-type: none"> <li>• Lip biting</li> <li>• Finger biting</li> <li>• Head banging</li> <li>• Banging of arms and legs</li> </ul>
Cri du Chat syndrome <sup>1</sup>	Deletion on chromosome 5p	Cat-like cry, intellectual disability, limited language development, sleep disturbances, hypersensitivity to auditory stimuli, vomiting, rumination	1:15,000–1:50,000 live births	76.8–92%	<ul style="list-style-type: none"> <li>• Head hitting</li> <li>• Scratching</li> <li>• Self-biting</li> </ul>
Prader-Willi syndrome <sup>11–14</sup>	Deletion of paternal 15q11-q13 region of chromosome 15	Hypotonia, intellectual delay, hypogonadism, dysmorphic features, short stature, obesity, behavioral and psychiatric manifestations	1:15,000 live births	70–90%	<ul style="list-style-type: none"> <li>• Skin picking</li> <li>• Nail biting</li> <li>• Hair pulling</li> </ul>
Pervasive developmental disorders (ASD, Asperger's disorder, Disintegrative disorder, Pervasive developmental disorder not otherwise specified) <sup>2, 15–19</sup>	Exact etiology unknown; combination of genetic, environmental, and neurobiological factors	Poor communication, social deficits, restrictive and stereotyped behaviors, hyperactivity, behavioral problems, tantrums, irritability, aggression	1:59 <sup>19</sup> individuals (ASD)	33–71%	<ul style="list-style-type: none"> <li>• Hitting</li> <li>• Self-biting</li> </ul>
Fragile X syndrome <sup>20–22</sup>	A single gene mutation on the X chromosome disrupts production of the fragile X mental retardation protein that regulates the production of proteins needed for maturation and elimination of synapses during brain development	Neurobehavioral phenotype with associated cognitive delay, aggression, impulsivity, anxiety	1:8000 females and 1: 4000 males	17–70%	<ul style="list-style-type: none"> <li>• Self-biting</li> <li>• Rubbing</li> <li>• Scratching</li> </ul>

(continued)

Table 1 (continued)

NDD	Etiology	Clinical Characteristics	Prevalence	Incidence of SIBs	Specific SIBs
Rett syndrome <sup>23–25</sup>	Loss of function mutations in the X-linked <i>MECP2</i> gene that leads to abnormal brain development and function	Stunted head growth, loss of acquired verbal skills, repetitive hand movements, ataxia, intellectual disabilities, and autistic-like behaviors	Females only, 1:10,000 live births	50%	<ul style="list-style-type: none"> <li>• Mouth hitting</li> </ul>
Cornelia de Lange syndrome <sup>26–28</sup>	De novo mutations in cohesion complex genes, such as the nipped-B-like-gene ( <i>NIPBL</i> ), that affect the protein network that regulates separation of chromatins during cell division	Multiple behavioral and developmental symptoms, abnormal limb development, growth delay, cardiac and genitourinary anomalies, myopia, hirsutism, sleep disturbance, and hearing loss	1:10,000–1:30,000 live births	40%	<ul style="list-style-type: none"> <li>• Face hitting (most classic)</li> <li>• Self-biting</li> <li>• Skin picking</li> </ul>
Down syndrome <sup>25</sup>	Attainment of extra copy of chromosome 21	Dysmorphic features, congenital malformations, endocrine disorders, obesity, hearing loss	1 in 700 live births	15%	<ul style="list-style-type: none"> <li>• Eye poking</li> </ul>

ASD = autism spectrum disorder; NDD = neurodevelopmental disorder; SIBs = self-injurious behaviors.

<sup>a</sup>The disorders highlighted in this table were chosen for two primary reasons: these disorders may be encountered by clinicians caring for children and youth with special health care needs (CSHCN); and published data exist pertaining to SIBs in these specific NDDs.

<sup>b</sup>NDDs are presented in order of descending incidence of SIBs.

<sup>c</sup>Hypoxanthine-guanine phosphoribosyl-transferase 1.

available evidence supporting select therapies is presented. A review of studies reporting outcomes for both irritability as well as SIBs are included due to the difficulty in teasing out reported outcomes specific to SIBs alone. When possible, specific theories pertaining to each presented pharmacologic agent as well as disease-specific information are included.

### General Approach to Assessment, Evaluation, and Management of SIBs in Children with NDDs

General knowledge of commonly used assessments and objective evaluation tools is important for managing patients with SIBs because it allows for interpretation of the literature, application to practice, choice of therapy, and determinations of therapeutic response. Applied behavior analysis (ABA) is a systematic approach to behavior intervention.<sup>36</sup> Functional behavioral assessment (FBA), the most common application of ABA to the assessment of SIBs, helps determine physical and social environmental causes of specific behaviors as well as frequency, duration, and contributing comorbidities and identification of a function-based behavioral

treatment.<sup>30, 37, 38</sup> FBAs include procedures such as interviews, informal observations, or functional analyses of SIBs.<sup>38, 39</sup> Objective tools most commonly used in the evaluation of irritability and SIBs include the Clinical Global Impressions Scale (CGI) and the irritability subscale of the Aberrant Behavior Checklist (ABC-I). The CGI refers to two physician-rated 7-point scales used to quantify overall symptom severity (CGI-S) and clinical improvement from baseline (CGI-I).<sup>40</sup> In ABC-I assessments, parents or teachers rate irritability based on 15 items using a 4-point scale that evaluates aggression, tantrums, unstable mood, and self-injury.<sup>40, 41</sup> An updated version of the global ABC scale, referred to as the ABC-C, is also available and intended to be more applicable to home and school settings.<sup>42</sup> These objective tools are cited as outcomes in several of the studies referenced in this review.

The general approach to assessing and managing SIBs in children with NDDs should be done in concert with a multidisciplinary team and involves a stepwise approach as follows:<sup>8</sup> 1) perform a comprehensive medical history and examination that assesses patient safety, level of functioning, and specific behaviors; 2) identify,

rule out, and address all contributing factors to behaviors; 3) perform ABA and FBA; 4) implement nonpharmacologic management and behavioral interventions;<sup>16</sup> and 5) initiate pharmacologic intervention.

### Nonpharmacologic Management

The American Academy of Pediatrics designated the prescription of behavioral treatment based on the results of a FBA as “best practice.”<sup>18</sup> Results of FBA lead to function-based, patient-specific treatment programs that determine aspects of the environment warranting change to reduce SIBs.<sup>43</sup> For example, if a child engages in SIB to escape from academic demands, a function-based approach would involve delivering escape from the demand contingent on a communication request (e.g., “break please”). A nonfunction-based approach would involve a time-out or contingent removal of the demand when SIBs occurs. Function-based behavioral treatments are more effective than nonfunction-based interventions, resulting in decreased use of punishment-based procedures.<sup>44</sup> The types of nonpharmacologic approaches are a critical component of the treatment plan for SIBs. When behavioral interventions alone fail to control SIBs, pharmacologic therapies can be considered; when implemented, pharmacotherapy must be combined with the existing behavioral interventions for optimal benefit.

### Pharmacologic Management

Most pharmacotherapy prescribing occurs off label, based on a paucity of robust evidence, clinical judgment on a case-by-case basis, and with an ongoing systematic approach to monitoring and justification of therapy. Because the precise pathophysiology of SIBs is yet to be defined, available pharmacotherapy primarily targets symptoms rather than the mechanism of disease.

Importantly, the available evidence for pharmacotherapies that target SIBs specifically is limited to lower levels of evidence. Well-designed studies are critically needed to better support pharmacotherapeutic decisions in practice. And most studies are performed in patients with ASD with subsequent extrapolation and application to other NDDs. When implementing pharmacotherapy, these factors may affect clinical response, yet the risks of therapy likely still apply. Despite

these limitations, the use and reliance on pharmacotherapy are common in practice.

Therefore, the choice of therapy must be determined using clinical judgment on a case-by-case basis (i.e., interpatient variability is high) accounting for factors such as cause, type and severity of SIBs, the child’s medical history and developmental age, pharmacokinetic and pharmacodynamic properties of medications, drug-drug and drug-disease interactions (e.g., sedation from multiple medications with central nervous system [CNS] depression actions), and available and applicable efficacy and safety data.<sup>45</sup> Once initiated, pharmacotherapy must be methodically monitored for individual response and ongoing rationale for continuation of therapy. In instances where the agent does not demonstrate a clear benefit, it should be discontinued. Appropriate therapy alterations must be based on the patient’s responses to therapy over the course of ongoing development and changes in clinical status.

To help clinicians faced with making difficult clinical decisions pertaining to the implementation of pharmacotherapy, the discussion here presents select pharmacologic agents (Table 2)<sup>12, 13, 33, 34, 40, 46-67</sup> with available supporting data in the management of SIBs in children with NDDs. The order presented does not reflect a treatment sequence; data supporting monotherapy are presented first, followed by evidence supporting dual therapy. Attempts have been made to present the highest level of evidence available for each agent. The studies selected for inclusion report SIBs-specific outcomes data. In studies that report SIBs data plus additional end points, summaries are provided for the benefit of the reader. When reviewing the data presented, readers should cautiously consider the strength of each piece of evidence when determining individual applicability. Additionally, statistical significance versus clinical significance should be considered. Numerical differences in outcome measures correlating to clinical significance are not universal or well defined in the literature; rather, clinical significance must be considered on a case-by-case basis dependent on symptom severity, individual response, and goals of care. Depending on the therapy, benefits may outweigh the risks of long-term use or vice versa. The data presented are intended to be used by clinicians to guide individualized patient-centered decisions.

Table 2. Review of Select Pharmacotherapy<sup>a</sup> with Evidence<sup>b</sup> for Management of Problem Behaviors in Children with Neurodevelopmental Disorders

Pharmacologic agent	Receptor effects	Available data	Specific NDDs studied	Ages of patients studied	Problem behavior types studied	Strength of evidence (GRADE) <sup>c</sup>	Dose <sup>d</sup>
Risperidone <sup>46–50</sup>	5-HT <sub>1A</sub> , 5-HT <sub>2A</sub> , 5-HT <sub>1B</sub> , 5-HT <sub>1C</sub> , 5-HT <sub>1D</sub> , and D <sub>2</sub> receptor agonist; $\alpha_1$ and $\alpha_2$ adrenergic receptor agonist	Randomized placebo-controlled trials; open-label extension trial	Pervasive developmental disorder, Down syndrome; fragile X syndrome <sup>49</sup>	5–16 yrs	<ul style="list-style-type: none"> <li>• Irritability</li> <li>• Aggression</li> <li>• SIB</li> <li>• Temper tantrums</li> </ul>	Irritability associated with ASD: High Other problem behaviors in other NDDs: Very low/Low	Initial: <20 kg: 0.25 mg/day ≥ 20 kg: 0.5 mg/day Titration: 0.25–0.5 mg at ≥ 2 wks Maintenance: <20 kg: 0.5 mg once/day or divided in 2 doses ≥ 20 kg: 1 mg once/day or divided in 2 doses Maximum: 3 mg/day
Aripiprazole <sup>51</sup>	Partial D <sub>2</sub> and 5-HT <sub>1A</sub> receptor agonist and 5-HT <sub>2A</sub> receptor antagonist	Case series; randomized placebo-controlled trials	ASD	6–17 yrs	<ul style="list-style-type: none"> <li>• Irritability</li> <li>• Aggression</li> <li>• SIB</li> <li>• Temper tantrums</li> </ul>	Irritability associated with ASD: High Other problem behaviors in other NDDs: Very low/Low	Initial: 2 mg once/day Titration: 5 mg increments each week Maintenance: 5–10 mg once/day Maximum: 15 mg once/day
Clomidine <sup>34, 52</sup>	$\alpha_2$ adrenoreceptor agonist; activates inhibitor neuron and reduces sympathetic outflow from the central nervous system	Case reports; open-label pilot study	Pervasive Developmental Disorder	5–13 yrs	<ul style="list-style-type: none"> <li>• SIBs</li> <li>• Aggression</li> </ul>	Very low Low	Initial: 0.025–0.05 mg/day (~0.002–0.003 mg/kg/day in younger children) Tolerated every 1–2 wks to target dose of 0.005–0.01 mg/kg/day in 3–4 divided doses Maximum: 0.01 mg/kg/day
N-Acetylcysteine <sup>40, 53–55</sup>	Prodrug of cysteine that restores glutathione and scavenges oxidants	Case report; randomized, double-blind, placebo-controlled studies	ASD; excoriation (skin picking) disorder (adults) <sup>56</sup>	4–50 yrs	<ul style="list-style-type: none"> <li>• Irritability</li> <li>• SIBs</li> <li>• Hyperactivity</li> </ul>	Low	Weight-based maximum (in 3–4 divided doses): 27–40.5 kg: 0.2 mg/day 40.5–45 kg: 0.3 mg/day >45 kg: 0.4 mg/day Initial dose: 500–600 mg once or twice/day Maintenance dose: 1800–2700 mg/day in 2 to 3 divided doses

(continued)



Table 2 (continued)

Pharmacologic agent	Receptor effects	Available data	Specific NDDs studied	Ages of patients studied	Problem behavior types studied	Strength of evidence (GRADE) <sup>c</sup>	Dose <sup>d</sup>
Riluzole <sup>33, 57</sup>	Inhibits glutamate release, enhances glutamate reuptake, inactivated voltage-dependent Na <sup>+</sup> channels	Case series; randomized double-blind placebo-controlled trial	Fragile X syndrome; ASD	5–20 yrs	<ul style="list-style-type: none"> <li>• Aggression</li> <li>• Irritability</li> <li>• SIBs</li> <li>• Repetitive behaviors</li> </ul>	Monotherapy: Very low Dual therapy with risperidone: Low	Children (5–12 yrs): Initial: 12.5 mg twice/day Maintenance: 10–40 kg: 25 mg twice/day > 40 kg: 50 mg twice/day Adolescents: Initial: 50 mg once/day Maintenance: 100 mg twice/day Initial: 2.5 mg/kg/day Maintenance dose: 2.5 mg/kg twice/day Weight-based maximum dose: <30 kg: 100 mg/day >30 kg: 150 mg/day Initial: 7.5 mg/day Titration: 7.5 mg every 1–2 wks Maximum: 45 mg/day in divided doses
Amantadine <sup>58, 59</sup>	Noncompetitive NMDA receptor antagonist	Double-blind placebo-controlled trials	ASD	4–19 yrs	<ul style="list-style-type: none"> <li>• Hyperactivity</li> <li>• Irritability</li> </ul>	Very low	
Mirtazapine <sup>60</sup>	Central presynaptic $\alpha_2$ adrenergic antagonist; 5HT <sub>2</sub> and 5HT <sub>3</sub> serotonin receptor antagonist; H <sub>1</sub> histamine receptor and peripheral $\alpha_1$ adrenergic and muscarinic antagonist	Naturalistic open-label study	Pervasive developmental disorders and ASD	3.8–23.5 yrs	<ul style="list-style-type: none"> <li>• Aggression</li> <li>• SIB</li> <li>• Irritability</li> <li>• Hyperactivity</li> </ul>	Very low	
Naltrexone <sup>61–63</sup>	Pure opioid antagonist with high affinity for $\mu$ opioid binding sites	Case reports; small case series; small studies	Prader-Willi syndrome	2–46 yrs	<ul style="list-style-type: none"> <li>• SIBs</li> <li>• Hyperactivity</li> </ul>	Very low	Fixed-dose: 50 mg/day Weight-based dosing: 0.5–2 mg/kg/day
Topical Anesthetics (EMLA) <sup>64</sup>	Stabilizes the neuronal membrane; inhibits ion influx, which is required for conduction of impulses	Case report	ASD	12-year-old	<ul style="list-style-type: none"> <li>• SIBs</li> </ul>	Very low	1 g applied to targeted site

(continued)

Table 2 (continued)

Pharmacologic agent	Receptor effects	Available data	Specific NDDs studied	Ages of patients studied	Problem behavior types studied	Strength of evidence (GRADE) <sup>c</sup>	Dose <sup>d</sup>
Topiramate <sup>12, 13, 65</sup>	Blocks neuronal voltage-dependent sodium channels; enhances GABA activity; antagonizes AMPA/kainite glutamate receptors; weakly carbonic anhydrase inhibitor	Open-label trial; double-blind placebo-controlled trial	ASD Prader-Willi syndrome	4–38 yrs	<ul style="list-style-type: none"> <li>• Irritability</li> <li>• Stereotypic behavior</li> <li>• Hyperactivity</li> <li>• SIBs</li> </ul>	Very low	Initial: 0.5–1 mg/kg/day Titration: 0.5–1 mg/kg every week Weight-based maintenance dose: <30 kg: 100 mg/day >30 kg: 200 mg/day
Divalproex <sup>66</sup>	Enhances GABA action and availability; mimics GABA action at postsynaptic receptor sites	Randomized double-blind, placebo-controlled trial	ASD	5–17 yrs	<ul style="list-style-type: none"> <li>• Irritability</li> </ul>	Very low	Initial: 10–15 mg/kg/day Weight-based dosing: Initial: <40 kg: 125 mg once/day ≥40 kg: 250 mg once/day Titration: 5–10 mg/kg/day at weekly intervals; titrate to effect Doses > 250 mg should be given in divided doses Initial: 5 mg/day Titration: 5 mg each week Weight-based maximum: <40 kg: 10 mg/day >40 kg: 20 mg/day in 2 divided doses
Buspirone <sup>67</sup>	5-HT <sub>1A</sub> and 5-HT <sub>1B</sub> receptor agonist and D <sub>2</sub> antagonist	Randomized double-blind placebo-controlled trial	ASD	4–17 yrs	<ul style="list-style-type: none"> <li>• Irritability</li> </ul>	Very low	

ASD = autism spectrum disorder; GABA =  $\gamma$ -aminobutyric acid; GRADE = Grading of Recommendations, Assessment, Development and Evaluations; NDDs = neurodevelopmental disorders; NMDA = N-Methyl-D-aspartic acid; SIBs = self-injurious behaviors.

<sup>a</sup>Pharmacologic agents are presented in the order presented in the article text. The order in which the agents are presented does not reflect a treatment algorithm; data supporting monotherapy are presented first, then followed by evidence supporting dual therapy.

<sup>b</sup>Data in this table were compiled and extrapolated from studies discussed in this review.

<sup>c</sup>Evidence was graded by the authors using the GRADE system for appraising studies. (Reference: Goldet G, Howick J. Understanding GRADE: an introduction. JEBM 2013;6:50–54.)

<sup>d</sup>Dosing suggestions have been compiled and extrapolated from studies discussed in this review. Dosing suggestions should always consult drug information resources and/or consult with a clinical pharmacist for the most up-to-date and patient-specific dosing recommendations when initiating therapy. Clinicians are urged to prescribe the most conservative initial dose, with titration to the lowest effective dose.

<sup>e</sup>Eutectic Marcaine lidocaine analgesic.

<sup>f</sup> $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.



## Review of Available Data: Monotherapy

### Second-generation Antipsychotics

Although no medications are approved by the U.S. Food and Drug Administration (FDA) specifically for treatment of irritability and SIBs secondary to NDDs, the second-generation antipsychotic (SGA) agents are commonly viewed as “first-line therapy.” This is owing to the body of supporting literature and FDA approval for irritability associated with ASD in children and adolescents. Although well-designed randomized controlled trials support the use of SGAs, no head-to-head comparisons exist to prove these agents are superior to other pharmacologic interventions for the treatment of SIB. Risperidone and aripiprazole gained FDA approval for the symptomatic management (aggression, self-injury, and temper tantrums) of children and adolescents with ASD in 2006 and 2009, respectively.<sup>68</sup> In a 2016 systematic review and meta-analysis, 11 randomized controlled trials of several pharmacologic agents used for the treatment of severe irritability and problem behaviors in children with ASD were analyzed.<sup>16</sup> Compared with placebo, risperidone and aripiprazole significantly improved ABC-I scores (Cohen’s *d* for efficacy: *d* = 0.9 and 0.8, respectively). A review of select studies and practical points is included here.

#### Risperidone

In an 8-week placebo-controlled trial, risperidone (0.25 mg/day for patients weighing less than 20 kg; 0.5 mg/day for patients 20 kg or more) was compared with placebo in 101 children and adolescents with ASD.<sup>46</sup> Doses were titrated to clinical response (mean dose 0.06 mg/kg/day). Scores on the ABC-I subscale were significantly reduced in the risperidone group (−56.9%) from  $26.2 \pm 7.9$  at baseline to  $11.3 \pm 7.4$  at 8 weeks compared with reductions in the placebo group scores (−14.1%) from  $25.5 \pm 6.6$  at baseline to  $21.9 \pm 9.5$  at 8 weeks ( $p < 0.001$ ). Adverse effects included weight gain, increased appetite, fatigue, drowsiness, dizziness, and drooling. In an open-label extension of this study, 63 patients were treated with risperidone (mean dose 0.05–0.07 mg/kg/day) for up to 4–6 months.<sup>47</sup> Sustained efficacy and acceptable tolerability were demonstrated, with increased appetite, weight gain, fatigue, and drowsiness as the most commonly reported adverse effects.

In another 8-week placebo-controlled study, 55 children with pervasive developmental disorders (PDDs) were randomized to receive risperidone 0.02–0.06 mg/kg/day given once or twice/day and titrated to clinical response (mean dose 0.05 mg/kg/day) or placebo.<sup>48</sup> Risperidone led to a significant reduction in the ABC-I subscale score, with a mean change of −13.4 (standard deviation [SD] 1.5) compared with −7.2 (SD 1.4) in the placebo group (6-point difference;  $p < 0.05$ ). Somnolence was the most frequently observed adverse effect in the risperidone group (74% vs 7% in the placebo group).

#### Aripiprazole

In an 8-week multicenter randomized double-blind placebo-controlled trial, aripiprazole at doses of 5 mg/day, 10 mg/day, or 15 mg/day was compared with placebo in 218 children 6–17 years of age with ASD and irritability, agitation, SIBs, or combined behaviors.<sup>51</sup> Compared with placebo, aripiprazole at all doses resulted in significant reductions in the ABC-I subscale score with treatment differences as follows: aripiprazole 5 mg/day, −4.0 (95% confidence interval [CI] −7.7 to −0.4,  $p = 0.032$ ), aripiprazole 10 mg/day, −4.8 (95% CI −8.4 to −1.3,  $p = 0.008$ ), aripiprazole 15 mg/day, −6.0 (95% CI −9.6 to −2.3,  $p = 0.001$ ). Mean clinician-rated CGI-I scores also demonstrated significant improvements across all doses compared with placebo: aripiprazole 5 mg/day, −0.7 ( $p = 0.003$ ), aripiprazole 10 mg/day, −0.8 ( $p < 0.001$ ), and aripiprazole 15 mg/day −0.8 ( $p < 0.001$ ). The most commonly reported adverse effects with aripiprazole were sedation, extrapyramidal symptoms (EPS), and weight gain. Short duration, fixed dosing, and restriction to the ASD population alone (rather than inclusion of other NDDs) limit study findings.

#### Other Second-Generation Antipsychotics

Limited robust data exist to support the use of other SGAs specifically for SIBs in children with NDDs. However, ziprasidone, olanzapine, and paliperidone were evaluated in case series, retrospective analyses, open-label, and small controlled studies for the management of other problem behaviors (e.g., irritability) in children with ASD.<sup>17, 69–73</sup>

Ziprasidone demonstrated moderate treatment response for irritability and aggression in children with ASD; however, compared with risperidone and aripiprazole, the evidence for effective

management of behaviors is weaker.<sup>17, 69</sup> Ziprasidone was well tolerated (e.g., weight neutral) in studies but carries an agent-specific risk for QTc interval prolongation, limiting its use in certain populations (e.g., patients with Rett syndrome) or patients concomitantly receiving medications that are QTc prolonging.

Olanzapine for aggression, disruptive or destructive behavior, and SIB was first reported in 20 adult patients with intellectual disability.<sup>70</sup> A significant decrease in target behaviors (i.e., aggression, SIBs, destructive or disruptive behaviors) was observed with olanzapine (mean reduction in SIB  $-7.9$ ,  $p < 0.044$ ); however, significant weight gain during the first 6 months of treatment ( $p < 0.006$ ) was reported. In a small (11 subjects) 8-week double-blind placebo-controlled trial in children with PDD with disruptive and repetitive behaviors, olanzapine was associated with a 50% response rate on the CGI-I rating scale.<sup>73</sup> Side effects included sedation, increased appetite, and substantial weight gain. Given limited data and a significant risk for weight gain as well as development of dyslipidemia, olanzapine should not be selected over other available SGAs at this time in children with NDDs.

Paliperidone for the treatment of irritability associated with ASD was studied in an 8-week open-label prospective study of 25 adolescents and young adults.<sup>71</sup> Paliperidone resulted in significant improvements in irritability with 21 patients experiencing greater than 25% reduction on the ABC-I subscale score (mean score at baseline 30.3 [SD 6.5]; mean score at end point 12.6 [SD 9.1],  $p = 0.0002$ ). These 21 patients were also considered treatment responders, defined by a CGI-I score of 1 or 2 ( $p < 0.0002$ ). Overall, paliperidone was well tolerated. Notably, a positive response to paliperidone was observed in patients with a history of nonresponse to risperidone. Additional advantages of paliperidone include lower risk for drug-drug interactions due to limited metabolism via the cytochrome P450 2D6 (CYP2D6) pathway and the ability to dose once/day. Larger, placebo-controlled trials with longer treatment durations are needed before widespread use of this agent.

As more knowledge is gained regarding the long-term efficacy and safety in specific NDDs, the role of these particular SGAs in practice will be further elucidated. To date, however, data are insufficient to support use of ziprasidone, olanzapine, and paliperidone over risperidone or aripiprazole, particularly for SIBs specifically.

Despite the demonstrated benefits of SGAs as a class and the often first-line role in therapy, significant adverse effects (e.g., weight gain, EPS including tardive dyskinesia and akathisia, QTc prolongation, sedation, hyperprolactinemia with subsequent osteoporosis, risk for venous thromboembolism, and metabolic abnormalities) coupled with the risk of drug-drug interactions often limit use in children with NDDs.<sup>74-76</sup> It is important to note the significance of EPS associated with SGAs. Tardive dyskinesia causes abnormal repetitive movements of the mouth, lips, tongue and, in some cases, distal limbs, and it is typically irreversible. Akathisia, defined as a subjective feeling of excessive restlessness, is treatable but has the potential to worsen SIBs, and it was associated with an increased risk of developing suicidal ideation.<sup>77, 78</sup> Even when the SGAs are tolerated, clinical response is frequently suboptimal requiring consideration of alternative medications.

### Clonidine

Clonidine binds to the  $\alpha_2$  adrenoreceptors in the CNS, thereby decreasing sympathetic outflow in specific regions of the brain (e.g., prefrontal cortex).<sup>79</sup> A proposed theory behind SIBs is that environmental stimuli may induce a state of hyperarousal.<sup>34</sup> Clonidine, by decreasing sympathetic outflow through stimulation of the inhibitory pathway, inhibiting the excitatory pathway, and exerting a direct effect on pain may be effective in minimizing this overarousal.<sup>79</sup> Despite frequent use in practice, data supporting clonidine specifically for SIBs are limited to two case reports. A 13-year-old girl with neurologic impairments and severe SIBs (skin picking, biting, poking and gouging of knees and face) resulting in infection was initiated on clonidine (0.05 mg/day, titrated to 0.05 mg 4 times/day).<sup>52</sup> After clonidine initiation, parent-reported benefits were observed in the total number of and surface area affected by SIBs. A second case report describes successful use of clonidine in a 9-year-old girl with PDD and severe, persistent SIB (pinching, scratching, rubbing of skin).<sup>34</sup> Initiation of clonidine at 0.025 mg/day and subsequent titration to 0.4 mg/day was associated with a dramatic decrease in surface tissue damage, number of injuries, intensity of skin trauma, and projected risk of further physical damage. In both cases, clonidine was well tolerated with the exception of transient decreased alertness and lethargy.

The available evidence lacks strength for SIBs alone; however, clonidine is commonly used in practice in children with NDDs, particularly those who have concomitant disrupted sleep and/or hyperarousal disorders due to the potential for additive benefit.<sup>80</sup> Clinicians should be vigilant about using clonidine in patients receiving other CNS-depressing agents, and those with baseline bradycardia, hypotension, or other cardiac conditions.

### N-acetylcysteine

N-acetylcysteine (NAC), an antioxidant and prodrug of cysteine, restores glutathione concentrations in the blood and brain and provides intracellular protection against reactive oxygen species. It is theorized that, in addition to antioxidant properties, NAC inhibits glutamate release through the glutamate-cysteine antiporter and decreases inflammation.<sup>40</sup> One theory related to the etiology of SIBs is an increase in excitatory signaling due to exaggerated glutamatergic transmission. Reducing this signaling may provide benefit in managing SIBs.

A case report of a 4-year-old boy with ASD and severe treatment-refractory SIBs describes a decrease in face gouging after initiation of NAC (450 mg/day with upward titration to 1800 mg/day).<sup>53</sup> In a larger (29 subjects) 12-week double-blind randomized placebo-controlled study, the use of NAC for behavioral disturbance in children with ASD was also successful.<sup>40</sup> Participants (3–12 yrs of age) were randomized to receive NAC (900 mg/day for 4 weeks, then titrated to 900 mg twice/day for 4 weeks, then 900 mg 3 times/day for 4 weeks, as tolerated) or placebo. Patients treated with NAC experienced significant improvements in the ABC-I subscale score from baseline to week 12 compared with placebo (mean decrease of  $-9.7$  compared with  $-1.7$ , respectively,  $p < 0.001$ ;  $d = 0.96$ ). There were no differences in adverse drug reactions; however, NAC was associated with gastrointestinal complaints.

Limitations to these data include small sample size, short duration, lack of long-term safety information, and studied populations that were limited to the ASD population. Further, no standardized dosing regimen for NAC has been established for this indication. NAC may be advantageous in select patients, particularly those who have failed other therapies or those receiving polypharmacy, given its minimal drug-drug interactions and relative safety profile. It is

primarily available as over-the-counter supplements, although one prescription product (i.e., Cetylev) is available. The prescription product is not approved for use specifically for SIB and may not be readily available in all pharmacies. The over-the-counter supplements are not regulated by the FDA; therefore, caution should be exercised when selecting these products, and insurance coverage may pose a challenge.<sup>81, 82</sup>

### Riluzole

Riluzole is a glutamate-modulating agent that exerts its effect via inhibition of glutamate release and enhanced reuptake at the presynaptic nerve terminal.<sup>57</sup> Originally approved for amyotrophic lateral sclerosis in 1995, riluzole has demonstrated clinical benefit in psychiatric disorders and may be a promising treatment option in the management of SIBs. Riluzole was proposed to exhibit noncompetitive blockade of  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors that play a critical role in fast excitatory synapse transmission, information processing, and behavioral plasticity.<sup>57</sup> Neuroprotective properties may also be attributable to inactivation of voltage-gated sodium channels and increased production of neurotrophic factors.

Early data from a 2011 case series demonstrate efficacy in three individuals (15, 18, and 20 yrs of age) with ASD and moderate to severe intellectual disability with SIBs and/or repetitive movements.<sup>33</sup> Riluzole was initiated at 50 mg/day in combination with the patients' other psychotropic medications and was titrated after 1 week to 50 mg twice/day for 4 weeks and then 100 mg twice/day thereafter. Each patient experienced a combination of improvements in behaviors on the CGI-S and CGI-I scales (e.g., decreased repetitive behaviors, aggression, and SIBs). Riluzole was well tolerated; the only notable side effect was anemia in one patient. Although this was a small case series, results support a rationale for further research regarding the use of riluzole for the management of SIBs.

Currently more than 50 ongoing clinical trials are assessing the efficacy of riluzole noted on clinicaltrials.gov for indications such as depression, fragile X syndrome, obsessive compulsive disorder, ataxia, pediatric bipolar disorder, irritability in ASD, Tourette syndrome, and other similar disorders. As riluzole makes its way into practice, clinicians should be aware of essential

monitoring parameters and potential drug interactions. Specifically, liver aminotransferases should be measured at baseline and every 3 months during therapy, and potential for drug interactions with CYP1A2 inducers and inhibitors should be carefully managed.

### Amantadine

Amantadine is a noncompetitive *N*-Methyl-D-aspartic acid (NMDA)-receptor antagonist with possible neuroprotective and antiinflammatory properties.<sup>58</sup> In a double-blind placebo-controlled study, 39 patients (5–19 yrs of age) with autistic disorder received amantadine 2.5 mg/kg/day (increased to 5 mg/kg/day after 1 week) or placebo for 4 weeks.<sup>59</sup> No significant difference in parent-recorded ABC-I ratings ( $p=0.178$ ) was observed between amantadine and placebo; however, CGI ratings were better in the treatment group with 53% of patients experiencing improvement compared with only 25% improvement in the placebo group,  $p=0.076$ : the estimated treatment difference in favor of amantadine was 27.6 percentage points (95% CI 57% to  $-1.8\%$ ,  $p=0.076$ ). Amantadine was well tolerated. Although the results were not statistically significant, a 28% difference in the number of patients who experienced improvement on the CGI scale in the amantadine group compared with placebo suggests potential for clinically meaningful benefits in refractory cases. Results are limited by short study period (4 wks), extrapolation of results from ASD population, and behaviors evaluated that are not specifically SIBs. Based on this single report, amantadine appears to have limited effect on irritability; however, further research is warranted.

### Mirtazapine

The involvement of serotonin was implicated in SIBs due to its established role in impulsivity and aggression as well as its connection with depression and suicide.<sup>1</sup> Due to its effect on the serotonin system, mirtazapine has been hypothesized to decrease symptoms such as aggression, irritability, and SIBs in patients with ASD.

The efficacy of mirtazapine (7.5–45 mg/day; mean 30 mg/day) in ASD was assessed in a 4-week naturalistic open-label study of 26 patients with PDD.<sup>60</sup> On the CGI-S and CGI-I scales, 34.6% and 30.8% of participants, respectively, were considered responders (“much improved” or “very much improved”) to mirtazapine.

Significant improvements were observed on the CGI-S scale ( $p<0.04$ ) and the CGI-I assessment of sleep ( $p<0.002$ ); however, no statistically significant differences were seen from baseline to end point for ABC-I (baseline =  $19.12 \pm 9.14$ ; end point =  $15.85 \pm 9.14$ ;  $p<0.08$ ). Importantly, although 11 patients had decreased irritability, reduction in SIBs was not specifically noted for any of the participants. Adverse effects associated with mirtazapine were mild and transient but included increased appetite, irritability, and sedation.

Based on this study, mirtazapine appears to have moderate efficacy in treating select behaviors associated with ASD; however, evidence is insufficient to support its use for management of SIBs alone. Mirtazapine has other efficacy benefits that may make it an appropriate choice in certain patients, such as for children with concomitant refractory insomnia, irritability, anxiety, or depression. Mirtazapine is associated with drowsiness, weight gain, elevated cholesterol, and anticholinergic effects, as well as drug-drug interactions due to its metabolism via CYP1A2.

### Pharmacotherapy Affecting Endogenous Opioid System and Pain Pathways

It was proposed that individuals who engage in SIBs may experience pain differently than those who do not.<sup>83</sup> One theory proposes that individuals with NDDs have a reduction in pain sensitivity.<sup>1, 2</sup> An opposing theory suggests an increased expression of pain. Although the exact relationship between pain and SIB remains unclear, the endogenous opioid system may be involved.<sup>2</sup> As a result, pharmacotherapy that targets pain processing and opioid binding has been evaluated.

### Naltrexone

Naltrexone is a pure opioid antagonist that exhibits high affinity for  $\mu$ -opioid binding sites. Its role in the treatment of SIBs evolved from the theory that SIBs stimulate release of endogenous endorphins that may drive some of the observed repetitive behavioral patterns.<sup>63</sup> Naltrexone was of great interest in the late 1980s and early 1990s.<sup>61</sup> However, available literature demonstrates conflicting efficacy results and is limited to case reports, small case series, and small controlled studies, with few studies specific to children.



A double-blind placebo-controlled crossover study examined the efficacy and safety of naltrexone (50 mg/day) in 33 adult patients with NDDs and SIBs.<sup>62</sup> On the total ABC and CGI-S scales, naltrexone did not demonstrate benefit compared with placebo. The authors do not report irritability subscale scores, but they state that a separate analysis performed on items specific for SIB in the ABC questionnaire also failed to show response. Observed side effects included fatigue, nausea, and sedation. These results are consistent with previously described placebo-controlled studies of naltrexone in patients with SIB and ASD.<sup>63</sup> In contrast, in a double-blind placebo-controlled crossover study of six male patients (15–31 yrs of age) with SIBs and mental disability, naltrexone 50 mg/day (0.6–1.5 mg/kg for 3 wks) resulted in significant reductions in the frequency of SIBs in two patients and a trend toward benefit in a third.<sup>84</sup> Similarly, in a single-subject (12-year-old girl with ASD) double-blind controlled analysis, naltrexone resulted in a zero rate of SIBs for 22 months.<sup>61</sup> The evidence regarding the use of naltrexone for treatment of SIBs is minimal and conflicting at best, and clinical use today has largely fallen out of favor. At present, naltrexone should be reserved for those patients who are refractory to other treatment options.

### *Topical Anesthetics*

Topical anesthetics inhibit ion influx required for conduction of impulses by stabilizing the neuronal membrane. The ability to block skin sensation may be useful in SIBs that are hypothesized to persist due to automatic reinforcement, defined as direct stimulation independent of environmental effects.<sup>64</sup> This theory was tested by applying 1 g eutectic Marcaine lidocaine analgesic (EMLA) to the cheeks of a 12-year-old boy with ASD, severe intellectual disability, and SIBs, refractory to other therapies.<sup>64</sup> The study was conducted over a 3-day period. Efficacy was measured by comparing the number of SIBs per minute after no application of anesthetic and after application of anesthetic. Application of anesthetic decreased the frequency of face slapping by 43% on day 1, 45% on day 2, and 26% on day 3. Despite observed benefit, generalizability of the results is limited by the single-subject unblinded observational study design and short treatment duration. Although topical anesthetic is generally well tolerated, a potential for systemic absorption and subsequent safety

concerns may be present. Incorporation of topical agents into the treatment plan for patients with SIBs is not routinely recommended and is restricted to select cases where SIBs is limited to a distinct and small topical area and risk for systemic absorption is minimal (e.g., an older patient with good skin integrity, no open wounds, and isolated face slapping).

### *Antiepileptics and Mood Stabilizers*

#### *Topiramate*

Although the precise mechanism by which topiramate reduces SIBs is unknown, modulation of GABA and glutamate activity likely plays a role.<sup>65</sup> Topiramate was reported to be effective in an 8-week open-label trial of three adults with Prader-Willi syndrome (PWS) as evidenced by improvement in SIBs (skin picking) in all patients following initiation of topiramate (starting dose 25 mg/day; maintenance dose 150–200 mg/day).<sup>12</sup> Similarly, an 8-week open-label study of eight adults with PWS demonstrated clinically significant improvement in SIB in seven individuals following the initiation of topiramate (initial dose 25 mg/day; maintenance dose 125–200 mg/day).<sup>13</sup> Scores on the self-injury and self-restraint checklist decreased from 2.12 at baseline to 1.25 after treatment with topiramate ( $p < 0.01$ ). These small open-label studies in adults suggest that topiramate could be an effective agent for the management of SIBs in patients with PWS but requires extrapolation from the adult population to pediatric practice.

#### *Other Antiepileptics*

The use of antiepileptics as mood stabilizers, specifically valproate, oxcarbazepine, levetiracetam, and lamotrigine, has been studied in the setting of behavioral problems associated with ASD. Most available evidence with this class does not specifically evaluate SIBs but rather focuses on assessing hyperactivity, impulsivity, aggression, and mood instability.<sup>85–87</sup> However, the efficacy of divalproex for the treatment of irritability in ASD was analyzed in a 12-week randomized double-blind placebo-controlled trial of 27 children (5–17 yrs old).<sup>66</sup> For patients receiving divalproex, improvement was seen in both ABC-I and CGI. Responders were defined as those who had CGI-I ratings of 1 or 2, indicating a substantial reduction in symptoms (divalproex 62.5% responders; placebo 9% responders).

Mean change in ABC-I scores from baseline to end of treatment was  $-7.5$  for divalproex and  $-2.6$  for placebo ( $p=0.048$ ). Divalproex was well tolerated overall, although one patient experienced a paradoxical increase in irritability related to insomnia, and another had clinically significant weight gain (more than 7% starting weight). An in-depth discussion of the agents in this class is not included here. The reader is referred to a comprehensive review of mood stabilizers in children and adolescents with ASD for further detail.<sup>85</sup>

Antiepileptics as mood stabilizers may play a role in the general management of children with NDDs, and theoretically a secondary benefit of decreasing irritability and possibly SIBs may be observed. However, data are lacking to support the use of these agents for SIBs alone.

## Review of Available Data: Dual Therapy

### Risperidone Plus NAC

Two double-blind randomized placebo-controlled trials of NAC in combination with risperidone demonstrated benefit in the treatment of ASD.<sup>54, 55</sup> The efficacy and safety of NAC (1200 mg/day in two divided doses) compared with placebo as augmentation of risperidone for treating irritability associated with ASD in 40 children with ASD (3.5–16 yrs of age) for 8 weeks was assessed.<sup>54</sup> Those receiving NAC experienced significant reductions in ABC-I subscale scores from baseline (mean baseline score 13.2 [SD 5.3] vs 9.7 [SD 4.1] after treatment) compared with placebo (mean baseline score 16.7 [SD 7.8] to 15.1 [SD 7.8] after treatment;  $p=0.035$ ). Adverse effects were uncommon; however, the NAC group experienced constipation, increased appetite, fatigue, nervousness, and daytime drowsiness. In another study, 50 patients (4–12 yrs of age) were randomized to receive risperidone plus NAC (600–900 mg/day in 3 divided doses) or risperidone plus placebo.<sup>55</sup> Twenty patients receiving NAC plus risperidone experienced a significantly greater reduction in irritability on the ABC-I subscale ( $p=0.02$ ) at week 10 compared with those who received placebo. The mean change on the ABC-I subscale from baseline to week 10 was 9.25 (SD 4.08) for the NAC plus risperidone group versus 5.35 (SD 3.23) in the placebo plus risperidone group. No significant differences in adverse effects were noted between groups. Compared with placebo, these data indicate that

NAC may provide benefit when added to risperidone.

### Risperidone Plus Riluzole

In a 2013 double-blind placebo-controlled randomized control trial, riluzole was studied as adjunctive treatment to risperidone, compared with placebo, for the management of irritability associated with ASD in 49 children 5–12 years of age.<sup>57</sup> Riluzole was initiated at 12.5 mg twice/day for 1 week and then titrated to 25 mg twice/day in patients weighing 10–40 kg and to 50 mg twice/day in patients greater than 40 kg for 9 weeks. Children in the riluzole group demonstrated significantly greater improvement in ABC-C irritability subscale score at week 10 compared with the placebo group ( $p=0.03$ ). Mean reduction in the ABC-C irritability subscale score from baseline to posttreatment was  $-9.55$  for children who received riluzole versus  $-5.85$  in the placebo group. Reduced Cohen's effect size was reported to indicate practical significance, which was moderate to high by week 10 ( $d = 0.70$ ). Adverse effects were similar between the two groups, with the exception of increased appetite and weight in the riluzole group. Compared with placebo, when added on to risperidone, riluzole improved the ABC-C and the CGI-I in children with behavioral symptoms associated with ASD.

### Risperidone Plus Amantadine

In a 10-week randomized double-blind placebo-controlled trial, risperidone plus amantadine was evaluated for effect in the treatment of ASD.<sup>58</sup> Forty patients were randomized to receive risperidone (1–2 mg/day) plus placebo or risperidone plus amantadine (100 mg for patients less than 30 kg or 150 mg for patients more than 30 kg). ABC-C subscale, adverse effects checklist, and CGI-I were assessed at 5 and 10 weeks. By week 10, patients in the risperidone plus amantadine group experienced significantly greater mean reductions in the irritability subscale score from baseline compared with placebo (mean difference 3.2, 95% CI 0.48 to 6.01,  $p=0.022$ ). Improvements in the CGI-I scores were also observed with 50% of patients in the amantadine group scoring as “very much improved” or “much improved” compared with 20% in the placebo group ( $p=0.047$ ). There were no significant adverse effects between groups. Limitations include short observational period,



small sample size, and fixed and relatively low dose of amantadine. Based on these outcomes, amantadine may have positive effect on irritability when used in combination with risperidone.

#### Risperidone Plus Topiramate

An 8-week double-blind placebo-controlled trial assessed the effect of risperidone (2 mg/day for patients less than 40 kg and 3 mg/day for patients more than 40 kg) plus topiramate (100 mg/day for patients less than 30 kg and 200 mg/day for patients more than 30 kg) in 40 children (4–12 yrs of age) compared with risperidone plus placebo in children with ASD.<sup>65</sup> On the ABC-I rating scale, a significant difference in irritability was observed for patients in the topiramate group with a mean difference of 9.05 from baseline to week 8 versus a mean difference of 1.5 in the placebo group ( $p \leq 0.0001$ ). Somnolence and decreased appetite were observed more frequently in those receiving topiramate.

#### Risperidone Plus Buspirone

Buspirone was hypothesized to play a role in irritability associated with ASD by boosting serotonin levels in the brain.<sup>67</sup> The theory is supported clinically in one randomized double-blind placebo-controlled trial of buspirone (10 mg/day in patients less than 40 kg or 20 mg/day in patients more than 40 kg) as an adjunct to risperidone (2 mg/day in patients less than 40 kg or 3 mg/day for patients more than 40 kg) in 40 children and adolescents with ASD. During the 8-week study duration, 81.2% of patients in the buspirone group compared with 38.9% of patients in the placebo group had a 30% or greater decline in irritability score.<sup>67</sup> The most common side effects observed in the buspirone group were increased appetite, drowsiness, and fatigue. Buspirone appears to be a safe and effective agent for children and adolescents with irritability in ASD. Buspirone may be considered for children with SIBs who have concomitant anxiety. However, clinicians should be aware that evidence is limited to a single small study.

Although each of these studies provides initial evidence supporting the use of risperidone in combination with other pharmacotherapy, the data are limited. Additional study is warranted to more conclusively confirm findings.

#### Other Therapies

Several additional novel treatment strategies and therapies, albeit with less supporting evidence, have been proposed or are under current investigation. A summary of these options is provided in Table 3.<sup>10, 88–95</sup>

#### Discussion/Conclusion

Managing SIBs in children with NDDs is critical both for the child and the family and caregivers, but it is often frustrating due to the refractory nature of the problem. No evidence-based guideline currently exists to guide clinicians in managing SIBs in children with NDDs. This is due to a lack of clear understanding of the underlying etiology and pathophysiology of SIBs, heterogeneity of NDDs, need to extrapolate data, and lack of robust supporting evidence specifically reported for SIBs. If SIBs are still present after resolving contributing factors and the implementation of nonpharmacologic interventions, initiation of pharmacologic management reliant on the most-up-to-date available evidence, clinical judgment on a case-by-case basis, and ongoing monitoring of treatment effects is necessary. Given the current supporting evidence and FDA approval, an SGA (i.e., risperidone or aripiprazole) may be considered first, accounting for drug-drug interactions as well as other patient safety parameters. If SIBs persist, individualized patient-specific factors should be considered including, but not limited to, diagnosed NDD, types of behaviors, risk for interactions and toxicities (e.g., these therapies are frequently used in combination with other medications with CNS-depressing actions), monotherapy versus dual therapy, and available evidence. The most conservative initial dosing is recommended with titration to the lowest effective dose. Routine and ongoing monitoring of therapeutic response and for safety is necessary. Individualized outcome measures appropriate for each patient should be identified to appropriately monitor and adjust pharmacotherapy and to maximize response.

The primary limitation of the presented evidence is that most studies examined children with ASD rather than specific NDDs. Although it is common for ASD or ASD-like symptoms to co-occur in NDDs, the unique pathophysiology and etiologies in each heterogeneous NDD may affect the degree to which a child responds to

Table 3. Review of Select Alternative Pharmacotherapy with Evidence for Management of Self-Injurious Behaviors in Children with Neurodevelopmental Disorders<sup>ab</sup>

Alternative agent	Mechanism of action	Rationale for use in self-injurious behaviors	Available data	Specific NDDs studied	Behaviors targeted	Ages studied	Suggested dosing	Clinical notes
Allopurinol <sup>88</sup>	Xanthine oxidase inhibitor; leads to decrease in uric acid	Inborn error of purine metabolism in Lesch-Nyhan syndrome leads to hyperuricemia, which has been associated with SIB	Case reports, case series (adults)	Lesch-Nyhan syndrome	<ul style="list-style-type: none"> <li>• SIB</li> <li>• Aggression</li> </ul>	54–80 yrs	Initial dose: 5–10 mg/kg/day Maintenance dose: 200–300 mg/day	Specific to Lesch-Nyhan syndrome
Baclofen <sup>89</sup>	Gamma-aminobutyric acid analog; crosses the blood-brain barrier and reduces excitatory stimulus in the cortex and basal ganglia	Some children with NDDs might be deficient in GABA	Double-blind crossover trial	Nonspecific	<ul style="list-style-type: none"> <li>• SIB</li> <li>• Aggression</li> </ul>	9–37 yrs	Initial: 10 mg 3 times/day (2.5 mg once/day for young, small, or fragile patients) Titration: Every 3 days to weekly Maintenance: 20–80 mg/day in divided doses (higher doses have been used with prolonged duration)	Patients may develop tolerance
Ecopipam <sup>90</sup>	Selective D1-dopamine receptor antagonist	Abnormal function of basal ganglia dopamine pathways has been proposed as mechanism of SIB in Lesch-Nyhan syndrome	Phase 1b, nonrandomized, dose-escalation safety study	Lesch-Nyhan syndrome	<ul style="list-style-type: none"> <li>• SIB</li> </ul>	9–52 yrs	Initial: 12.5 mg/day Titration: Double the dose every 2 days, as tolerated Maintenance: 200 mg/day Initial: 0.25 mg once/day Titration: Increase by 0.25 mg each week Maintenance: 5 mg divided 1 to 2 times/day	Experimental therapy <sup>90</sup> Specific to Lesch-Nyhan syndrome
Fluphenazine <sup>91</sup>	First-generation antipsychotic; D1-receptor antagonist	SIBs in Lesch-Nyhan syndrome may be caused by supersensitivity to dopamine <sup>91</sup>	Case report of two patients	Lesch-Nyhan syndrome	<ul style="list-style-type: none"> <li>• SIB</li> </ul>	20 mo; 15-year-old	Initial: 0.25 mg once/day Titration: Increase by 0.25 mg each week Maintenance: 5 mg divided 1 to 2 times/day	Studied as add-on therapy to various baseline medications Acts like a second-generation antipsychotic at low doses
Loxapine <sup>92</sup>	Medium potency, dibenzoxazine antipsychotic; D1, D2, D4 antagonist	Proposed to induce changes in cerebral subcortical inhibitory areas of the brain leading to suppression of aggression	Prospective open-label trial	ASD	<ul style="list-style-type: none"> <li>• Irritability</li> </ul>	13–65 yrs	5–15 mg/day (low dose)	

(continued)

Table 3 (continued)

Alternative agent	Mechanism of action	Rationale for use in self-injurious behaviors	Available data	Specific NDDs studied	Behaviors targeted	Ages studied	Suggested dosing	Clinical notes
Pioglitazone <sup>93</sup>	Potent, selective agonist of peroxisome proliferator-activated receptor-gamma	Crosses the blood-brain barrier and may decrease inflammation in the cortex of patients with ASD	Randomized double-blind placebo-controlled trial (combination therapy only)	ASD	<ul style="list-style-type: none"> <li>Irritability</li> </ul>	4-12 yrs	15 mg twice/day	Substrate of CYP <sup>c</sup> 2C8 (major); CYP3A4 (minor) Pharmacodynamic interactions with hypoglycemic medications
Vitamin B12 <sup>94</sup>	Co-factor of antioxidants; stimulates regeneration of methionine	Physiologic abnormalities such as oxidative stress and inflammation have been associated with symptoms of ASD	Small, pilot, randomized controlled trial; large, randomized controlled trial	ASD	<ul style="list-style-type: none"> <li>Nonspecific</li> </ul>	3-8 yrs	64.5 µg/kg subcutaneously every three days	Conflicting outcomes Assess behavioral symptoms in general; primary outcome was overall improvement based on CGI
5-hydroxytryptophan <sup>10, 95</sup>	Precursor for the synthesis of serotonin	Hypoxanthine-guanine phosphoribosyltransferase enzyme deficiency in Lesch-Nyhan syndrome leads to dysfunction of cholinergic and serotonergic systems; increase in 5-hydroxytryptophan synthesis has been proposed to stimulate receptors	Open-label trial; double-blind clinical trial of one patient	Lesch-Nyhan syndrome	<ul style="list-style-type: none"> <li>SIB</li> </ul>	1-12 yrs	8 mg/kg	Specific to Lesch-Nyhan syndrome Conflicting outcomes

NDDs = Neurodevelopmental disorders; ASD = autism spectrum disorder; GABA = gamma-aminobutyric acid; SIBs = Self-injurious behaviors

<sup>a</sup>Alternative pharmacologic agents are presented in alphabetical order.

<sup>b</sup>Data in this table have been compiled and extrapolated from studies discussed in this review as well as the LexiComp and Micromedex databases. Although these dosing recommendations are meant to provide guidance on the usual dosing ranges for these understudied agents, prescribing clinicians should always consult drug information resources and/or consult with a clinical pharmacist for the most up-to-date and patient-specific dosing recommendations when initiating therapy. Clinicians are urged to prescribe the most conservative initial dose, with titration to the lowest effective dose.

<sup>c</sup>Cytochrome P450.

therapy. Second, the outcome measures and assessment scales used in clinical trials, such as ABC-I and CGI, provide information for a combination of behaviors and do not distinguish between unique symptoms. Many studies also rely on unstandardized subjective assessments of behavior to draw conclusions. Both of these concerns limit the ability to evaluate rigorously the treatment effects of individual medications specifically on SIBs. Finally, as emphasized throughout the review, the available evidence is weakened by small sample size, potential for bias, lack of long-term follow-up (e.g., in many cases studies limited to weeks), and restricted generalizability.

These limitations notwithstanding, this review presents the nonpharmacologic and pharmacologic management strategies for SIBs, as well as the best available supporting evidence. Still, many unanswered clinical questions exist regarding the treatment of SIBs in patients with NDDs. Opportunities for future research to advance knowledge around the management of SIBs include the need for more rigorous research studies including prospective investigations in specific subpopulations of children with NDDs, the use of standardized symptom measurement instruments, and study durations adequate to assess important long-term outcomes; the conduct of head-to-head medication trials; and, the evaluation of novel combinations of therapies including dual pharmacologic therapy or mixed pharmacologic and nonpharmacologic interventions. Until more data are available, clinicians must continue to rely on the limited available evidence, clinical judgment and expertise, and carefully monitored response(s) to therapy when managing SIBs in children with NDDs.

### Funding Source

James Feinstein was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (NIH) under Award Number K23HD091295. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by NIH or the U.S. government.

### References

1. Crapper L, Ernst C. Comparative analysis of self-injury in people with psychopathology or neurodevelopmental disorders. *Pediatr Clin North Am* 2015;62:619–31.

2. Devine DP. Self-injurious behaviour in autistic children: a neuro-developmental theory of social and environmental isolation. *Psychopharmacology* 2014;231:979–97.
3. Furniss F, Biswas AB. Recent research on aetiology, development and phenomenology of self-injurious behaviour in people with intellectual disabilities: a systematic review and implications for treatment. *J Intellect Disabil Res* 2012;56:453–75.
4. van Loo KM, Martens GJ. Genetic and environmental factors in complex neurodevelopmental disorders. *Curr Genomics* 2007;8:429–44.
5. Grigg-Damberger M, Ralls F. Treatment strategies for complex behavioral insomnia in children with neurodevelopmental disorders. *Curr Opin Pulm Med* 2013;19:616–25.
6. Stores G. Sleep-wake function in children with neurodevelopmental and psychiatric disorders. *Semin Pediatr Neurol* 2001;8:188–97.
7. Ianni HF, Abreu TC, Fidelis Sde M, Correa H, Kummer A. Prevalence of self-injurious behavior in people with intellectual development disorder. *Rev Bras Psiquiatr* 2015;37:266–7.
8. McGuire K, Fung LK, Hagopian L, et al. Irritability and problem behavior in autism spectrum disorder: a practice pathway for pediatric primary care. *Pediatrics* 2016;137(Suppl 2):S136–48.
9. Colley AF, Leversha MA, Voullaire LE, Rogers JG. Five cases demonstrating the distinctive behavioural features of chromosome deletion 17(p11.2 p11.2) (Smith-Magenis syndrome). *J Paediatr Child Health* 1990;26:17–21.
10. Mizuno TI, Yugari Y. Letter: self-mutilation in Lesch-Nyhan syndrome. *Lancet* 1974;1:761.
11. Foundation for Prader-Willi Research. Available from [www.fpw.org/about-prader-willi-syndrome](http://www.fpw.org/about-prader-willi-syndrome). Accessed July 12, 2018.
12. Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK. Topiramate attenuates self-injurious behaviour in Prader-Willi syndrome. *Int J Neuropsychopharmacol* 2002;5:141–5.
13. Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ. Effects of topiramate in adults with Prader-Willi syndrome. *Am J Ment Retard* 2004;109:301–9.
14. Buono S, Scannella F, Palmigiano MB. Self-injurious behavior: a comparison between Prader-Willi syndrome, Down syndrome and autism. *Life Span and Disability XIII* 2010;2:187–201.
15. Richards C, Oliver C, Nelson L, Moss J. Self-injurious behaviour in individuals with autism spectrum disorder and intellectual disability. *J Intellect Disabil Res* 2012;56:476–89.
16. Fung LK, Mahajan R, Nozzolillo A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. *Pediatrics* 2016;137(Suppl 2):S124–35.
17. Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. *J Child Adolesc Psychopharmacol* 2007;17:779–90.
18. Myers SM, Johnson CP, American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. *Pediatrics* 2007;120:1162–82.
19. Autism Speaks. Available from <https://www.autismspeaks.org/what-autism/prevalence>. Accessed July 12, 2018.
20. Erickson CA, Weng N, Weiler IJ, et al. Open-label riluzole in fragile X syndrome. *Brain Res* 2011;1380:264–70.
21. Hall SS, Lightbody AA, Reiss AL. Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. *Am J Ment Retard* 2008;113:44–53.
22. Moskowitz LJ, Jones EA. Uncovering the evidence for behavioral interventions with individuals with fragile X syndrome: a systematic review. *Res Dev Disabil* 2015;38:223–41.
23. Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. *Nat Rev Neurosci* 2018;19:368–82.
24. Oliver C, Murphy G, Crayton L, Corbett J. Self-injurious behavior in Rett syndrome: interactions between features of Rett syndrome and operant conditioning. *J Autism Dev Disord* 1993;23:91–109.

25. Huisman S, Mulder P, Kuijk J, et al. Self-injurious behavior. *Neurosci Biobehav Rev* 2018;84:483–91.
26. Genetics Home References: Cornelia de Lange Syndrome. Available from <https://ghr.nlm.nih.gov/condition/cornelia-de-lange-syndrome>. Accessed July 12, 2018.
27. Grados MA, Alvi MH, Srivastava S. Behavioral and psychiatric manifestations in Cornelia de Lange syndrome. *Curr Opin Psychiatry* 2017;30:92–6.
28. Tonkin ET, Wang TJ, Lisgo S, Bamshad MJ, Strachan T. NIPBL, encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B, is mutated in Cornelia de Lange syndrome. *Nat Genet* 2004;36:636–41.
29. Oliver C, Richards C. Practitioner Review: Self-injurious behaviour in children with developmental delay. *J Child Psychol Psychiatry* 2015;56:1042–54.
30. Matson JL, Turygin NC. How do researchers define self-injurious behavior? *Res Dev Disabil* 2012;33:1021–6.
31. Lecavalier L, Leone S, Wiltz J. The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. *J Intellect Disabil Res* 2006;50:172–83.
32. Beavers GA, Iwata BA, Lerman DC. Thirty years of research on the functional analysis of problem behavior. *J Appl Behav Anal* 2013;46:1–21.
33. Wink LK, Erickson CA, Stigler KA, McDougle CJ. Riluzole in autistic disorder. *J Child Adolesc Psychopharmacol* 2011;21:375–9.
34. Blew P, Luiselli JK, Thibadeau S. Beneficial effects of clonidine on severe self-injurious behavior in a 9-year-old girl with pervasive developmental disorder. *J Child Adolesc Psychopharmacol* 1999;9:285–91.
35. Robey KL, Reck JF, Giacomini KD, Barabas G, Eddey GE. Modes and patterns of self-mutilation in persons with Lesch-Nyhan disease. *Dev Med Child Neurol* 2003;45:167–71.
36. Fisher WW, Piazza CC, Roane HS. *Handbook of applied behavior analysis*. New York, NY: Guilford Press; 2011.
37. Autism Research Institute: Self-Injury. Available from [https://www.autism.com/symptoms\\_self-injury](https://www.autism.com/symptoms_self-injury). Accessed January 4, 2019.
38. Hanley GP, Iwata BA, McCord BE. Functional analysis of problem behavior: a review. *J Appl Behav Anal* 2003;36:147–85.
39. Iwata BA, Dorsey MF, Slifer KJ, Bauman KE, Richman GS. Toward a functional analysis of self-injury. *J Appl Behav Anal* 1994;27:197–209.
40. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. *Biol Psychiatry* 2012;71:956–61.
41. Carroll D, Hallett V, McDougle CJ, et al. Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. *Child Adolesc Psychiatr Clin N Am* 2014;23:57–72.
42. Aman M, Singh N. *The aberrant behavior checklist-community*. East Aurora, NY: Slosson Educational Publications, Inc.; 1994.
43. Tiger JH, Hanley GP, Bruzek J. Functional communication training: a review and practical guide. *Behav Anal Pract* 2008;1:16–23.
44. Didden R, Duker PC, Korzilius H. Meta-analytic study on treatment effectiveness for problem behaviors with individuals who have mental retardation. *Am J Ment Retard* 1997;101:387–99.
45. McMahon AW, Dal Pan G. Assessing drug safety in children—the role of real-world data. *N Engl J Med* 2018;378:2155–7.
46. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2002;347:314–21.
47. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. *Am J Psychiatry* 2005;162:1361–9.
48. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. *J Autism Dev Disord* 2007;37:367–73.
49. Dominick KC, Wink LK, Pedapati EV, Shaffer R, Sweeney JA, Erickson CA. Risperidone treatment for irritability in fragile X syndrome. *J Child Adolesc Psychopharmacol* 2018;28:274–8.
50. Kent JM, Hough D, Singh J, Karcher K, Pandina G. An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. *J Child Adolesc Psychopharmacol* 2013;23:676–86.
51. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. *J Am Acad Child Adolesc Psychiatry* 2009;48:1110–19.
52. Symons FJ, Thompson A, Realmuto G. Clonidine for self-injurious behavior. *J Am Acad Child Adolesc Psychiatry* 2004;43:1324–5.
53. Marler S, Sanders KB, Veenstra-VanderWeele J. N-acetylcysteine as treatment for self-injurious behavior in a child with autism. *J Child Adolesc Psychopharmacol* 2014;24:231–4.
54. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. *BMC Psychiatry* 2013;13:196.
55. Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. *Clin Neuropharmacol* 2015;38:11–17.
56. Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. *JAMA Psychiatry* 2016;73:490–6.
57. Ghaleiha A, Mohammadi E, Mohammadi MR, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. *Paediatr Drugs* 2013;15:505–14.
58. Mohammadi MR, Yadegari N, Hassanzadeh E, et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. *Clin Neuropharmacol* 2013;36:179–84.
59. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. *J Am Acad Child Adolesc Psychiatry* 2001;40:658–65.
60. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 2001;11:267–77.
61. Barrett RP, Feinstein C, Hole WT. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. *Am J Ment Retard* 1989;93:644–51.
62. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, van Engeland H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. *Arch Gen Psychiatry* 1995;52:766–73.
63. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. *J Am Acad Child Adolesc Psychiatry* 1993;32:1283–91.
64. Kern L, Bailin D, Mauk JE. Effects of a topical anesthetic on non-socially maintained self-injurious behavior. *Dev Med Child Neurol* 2003;45:769–71.
65. Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2010;34:1269–72.
66. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. *Neuropsychopharmacology* 2010;35:990–8.



67. Ghanizadeh A, Ayoobzadehshirazi A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. *Pediatr Neurol* 2015;52:77–81.
68. Malone RP, Waheed A. The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism. *Drugs* 2009;69:535–48.
69. Dominick K, Wink LK, McDougle CJ, Erickson CA. A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder. *J Child Adolesc Psychopharmacol* 2015;25:397–401.
70. Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. *J Clin Psychiatry* 2003;64:1258–65.
71. Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. *Psychopharmacology* 2012;223:237–45.
72. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. *J Am Acad Child Adolesc Psychiatry* 2002;41:921–7.
73. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. *J Child Adolesc Psychopharmacol* 2006;16:541–8.
74. Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. *JAMA Psychiatry* 2013;70:1067–75.
75. Calarge CA, Burns TL, Schlechte JA, Zemel BS. Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. *J Clin Psychiatry* 2015;76:607–13.
76. Zhang R, Dong L, Shao F, Tan X, Ying K. Antipsychotics and venous thromboembolism risk: a meta-analysis. *Pharmacopsychiatry* 2011;44:183–8.
77. Nepal H, Black E, Bhattarai M. Self-harm in sertraline-induced akathisia. *Prim Care Companion CNS Disord* 2016;18 <https://doi.org/10.4088/PCC.16l01952>.
78. Pringsheim T, Doja A, Belanger S, Patten S; Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. *Paediatr Child Health* 2011;16:590–8.
79. Kempf JP, DeVane CL, Levin GM, Jarecke R, Miller RL. Treatment of aggressive children with clonidine: results of an open pilot study. *J Am Acad Child Adolesc Psychiatry* 1993;32:577–81.
80. Blackmer AB, Feinstein JA. Management of sleep disorders in children with neurodevelopmental disorders: a review. *Pharmacotherapy* 2016;36:84–98.
81. Bent S, Hendren RL. Complementary and alternative treatments for autism part I: evidence-supported treatments. *AMA J Ethics* 2015;17:369–74.
82. Gabay M, Smith JA, Chavez ML, et al. White paper on natural products. *Pharmacotherapy* 2017;37:e1–15.
83. Courtemanche AB, Black WR, Reese RM. The relationship between pain, self-injury, and other problem behaviors in young children with autism and other developmental disabilities. *Am J Intellect Dev Disabil* 2016;121:194–203.
84. Kars H, Broekema W, Glaudemans-van Gelderen I, Verhoeven WM, van Ree JM. Naltrexone attenuates self-injurious behavior in mentally retarded subjects. *Biol Psychiatry* 1990;27:741–6.
85. Canitano R. Mood stabilizers in children and adolescents with autism spectrum disorders. *Clin Neuropharmacol* 2015;38:177–82.
86. Rugino TA, Samsoc TC. Levetiracetam in autistic children: an open-label study. *J Dev Behav Pediatr* 2002;23:225–30.
87. Wasserman S, Iyengar R, Chaplin WF, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. *Int Clin Psychopharmacol* 2006;21:363–7.
88. Carr CN, Straley CM, Baugh TB. Allopurinol for the treatment of refractory aggression: a case series. *Pharmacotherapy* 2017;37:748–54.
89. Primrose DA. Treatment of self-injurious behaviour with a GABA (gamma-aminobutyric acid) analogue. *J Ment Defic Res* 1979;23:163–73.
90. Khasnavis T, Reiner G, Sommerfeld B, Nyhan WL, Chipkin R, Jinnah HA. A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease. *Mol Genet Metab* 2016;117:401–6.
91. Goldstein M, Anderson LT, Reuben R, Dancis J. Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation. *Lancet* 1985;1:338–9.
92. Hellings JA, Reed G, Cain SE, et al. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. *J Child Adolesc Psychopharmacol* 2015;25:150–9.
93. Ghaleiha A, Rasa SM, Nikoo M, Farokhnia M, Mohammadi MR, Akhondzadeh S. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. *Psychiatry Res* 2015;229:181–7.
94. Bertoglio K, Jill James S, Deprey L, Brule N, Hendren RL. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. *J Altern Complement Med* 2010;16:555–60.
95. Frith CD, Johnston EC, Joseph MH, Powell RJ, Watts RW. Double-blind clinical trial of 5-hydroxytryptophan in a case of Lesch-Nyhan syndrome. *J Neurol Neurosurg Psychiatry* 1976;39:656–62.

## Supporting Information

The following supporting information is available in the online version of this paper:

Table S1. Relevant Search Terms used to Identify Included Data.